<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 142 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page141.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=142">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 142 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 142</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=142"><img src="../thumb/142.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Cardio-Vascular Agents - 7.3.8                                                 2020-04 / 111
       with high flux membr.& hymenoptera desensitisat.treatm., concom.   RAMPIL, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  discont.1 day bef. maj. surg./anaesthes., cerebrovasc.dis./ischaem.
       thiaz.diuretics., imp.liv.funct., vol.&/salt deplet.pts., adeq.hydrat., due   Ramipril  heart dis., hyperkalaem., diab.mellit., dual block.of RAAS with ARB’s/
       to hypokalaem.risk med.induc.torsades de pointes, monit.QT-interv.,   Indications: Mild to mod.hypertens., card.fail. follow.MI., reduc.  ACE inhibit./aliskiren assoc.with high. freq.hypotens./hyperkalaem.&
       concom. metformin., iodinat.contrast med.incr.risk of ac.ren.insuf-  proteinur.& glomerul.filtrat.rate decline in diabet.nephropathy &   decr.ren. funct., lact.intol., concom.K+supplem., vol.&/salt deplet. pts
       fic.in pres.of dehydrat., poss.aggrav. of pre-exist.ac.dissemin.lupus   hypertens., reduc. risk. of.MI./stroke, or card.vasc.death & need for   correct.salt/vol.deplet.bef.init.ther.& monit thereaft, incr.BP monit.
       erythematos., funct. ren.insuffic., elderly, ischaem.heart dis./cerebr.   revascularisat.proced.in pts with incr.CV risk, reduc.risk. of.MI, stroke,   when NSAID add./ discont., monit.ser.Li.conc., teratogenic aft.1   st
       circulat. insuffic., sev.card.insuffic.& insul.depend. diab., surg./an-  or card.vasc.death in. diab. pt.  trimester, concom.diuret.
       aesthes., L ventric.outflow tract obstruct., discont.ther.if jaund./elev.  (S3) CAPS. A39/7.1.3/0141, 0142, 0143, 0144  Interactions: Addit.antihypertens.eff.with diuret./ alcoh.& hypotens.
                               +
       hepat.enzym. noted, hyperkalaem.risk fact., monit.Na, K & Ca lev.,   705426-001: 1,25 mg, 30, R106,66  produc.meds, NSAID’s & high dos. salicylate poss.reduc.antihyper-
                                                                                 +
                                                                                      +
       discont.ther.bef.investig.parathyroid funct.  705427-001: 2,5 mg, 30, R129,48  tens.eff., poss. hyperkalaem. with K  supplem./K  salt substit./K -spar.
                                                                                            +
       Drug interactions: Ser.Li incr.& Li toxic.risk incr., baclofen/TCA’s/  705428-001: 5 mg, 30, R195,69  diuret./aliskiren/ACE-inhibits./ARBs/ NSAIDs/ heparins/immunosup-
       neurolept. & cert.anaesth.agents incr. antihypertens.eff., concom.  705429-001: 10 mg, 30, R197,54  press.agents, trimethoprim., Li conc.incr., incr.adverse eff.risk with
       NSAID’s/high dos. acetylsalicylic acid/corticoster.& tetracosactide   Dosage: Admin.at approx.same time each day with/-out food.  estramustine, baclofen potent. antihypertens. eff., poss.excess.BP
       reduc. antihypertens.eff., hypotens.eff.incr.by other antihypertens.esp.  Hypertens: Init.2,5 mg dly in pts.not on diuret. Incr.to 5 mg and   reduct.with diurets., hypoglycaem. eff.of insul.& hypoglycaem.agents
       when combin.with diuret., poss. hyperkalaem.with K supplem./K  salt   max.10 mg dly at 1-2 wk. interv.depend.on respon. Dos.range: 2,5-  incr., incr. hypotens.eff.with cert.anaesthet./ TCA’s/ anti-psychot./
                            +
                                 +
           +
       substit./ K -spar.diuret./aliskiren/ACE-inhibits./ ARBs/NSAIDs/hep-  10 mg. Full therapeut.eff.may take sev.wks. If desir.eff.not achiev.  nitroglycer.& other nitrat./ other vasodilat., incr.angio-oed.risk with
       arins/immunosuppress.agents, incr.angioneurot.oed.with concom.  within 2-4 wks.incr.dos.  concom. gliptines., reduc.antihypertens.eff.with sympathomimets.,
       estramustine., poss. incr. hypoglycaem.eff.with insul./ sulphonylur.,   MI/stroke/CV death risk reduct.: Init: 2,5 mg once dly. Incr.at 4   nitritoid reacts.report.with inj.gold,
       incr.angio-oedem.risk with concom. gliptines., allopurin./cytostat/   wk.interv.until therapeut.eff. achiev.bas.on clinic.respons. Implement
       immunosuppress. agents / system.corticoster & procainamide incr.   incr.by doubl.dos. aft.one wk & doubl. again aft.3 wks. to norm.maint.  REAPTAN, (Biogaran) Servier [P/S]
       leucopen. risk, nitritoid reacts.report.with inj.gold, IV amphotericin B/  dos.of 10 mg once dly.  Perindopril arginine 5(5;10;10) mg, amlodipine besilate 5(10;5;10) mg
       glucocortic./mineralocortic.& stimul.laxat. incr.risk of low K lev.effs.,   Non-diabet.& diabet.nephropathy: Init. 1,25 mg dly. Adjust ac-  Indications: Hypertens.in pts.already stabilis. with perindopril &
                               +
       digox.tox. effs.favour.by low.K lev., reduc.urin.Ca eliminat., poss. incr.  cord.to clinic.respons. doubl.dos.at 2-3 wk.interv. Max.10 mg dly.   amlodipine at equiv.dos., pts. uncontr. on either perindopril or am-
                   +
       Ca lev.with Ca salts, cyclospor.may incr. creatinine lev.  Post MI: Init. 2,5 mg 2xdly x2 days 3-10 days aft.ac.MI if heart fail   lodipine monother.
                                                                  (S3) TABS, 43/7.1.3/0929, 0930, 0931, 0932
       RAMIPRIL HEXAL, Sandoz [P/S]  manifests & pt. haemodynamic stable. Incr.to 5 mg 2xdly if well tol. If   3001150-001 5/5 mg, 30, R132,90
       Ramipril                      init. dos.of 2,5 mg not tol.init.with 1,25 mg 2xdly incr. to 2,5 mg 2xdly.  3001157-001 5/10 mg, 30, R155,70
       Indications: Mild to mod.hypertens., card.fail. follow.MI., reduc.  High risk. indiv: Discont.diuret.2-3 days bef.init ther. Where diu-  3001158-001 10/5 mg, 30, R165,00
       proteinur.& glomerul.filtrat.rate in pts.with diabet.nephropathy &   ret.cannot.be discont.init. with 1,25 mg dos. Subseq.dos.adjustm.  3001159-001 10/10 mg, 30, R170,70
       hyperten., reduc. risk. of.MI. stroke, or card.vasc.death & reduc.  depend.therapeut. respon.  Dosage: 1 tab.dly.as sngl.dos.pref.in morn.bef. food. Fix.dos.com-
       need for revascularisat.proced.in pts with incr.CV risk, reduc. risk.  Contraindications: Angioed.hist.relat.to ACE inhibit./ARB ther.,   bin.not suit.for init.ther.
       of.MI.stroke,or card.vasc.death in.diab. pt.  heredit./idiopathic angioed., aort.stenos., hypertrop. obstruct.car-  Contraindications: Angioed.hist.link.to prev. ACE inhibit./ARB’s,
       (S3) TABS. 37/7.1.3/0511, 0512  diomyopathy, sev imp.ren funct., ren.artery stenos.in pts.with sngl.  heredit./idiopath.angioed., hypertroph. obstruct.cardiomyopathy, sev.
                                           +
       704374-001: 2,5 mg, 30, R131,56  kidn., concom.K  spar.diuret.ther., porphyr., Li ther., safety & effic in   ren. funct. impairm., aort./bil.ren.art.stenos., ren.art. stenos./ bilat.ren.
       704375-001: 5 mg, 30, R197,46  childr.not est., pregn., safety in lactat.not est.  art.stenos.in pts.with sngl. kidn., porphyr., concom.K -spar.diurets./
                                                                                        +
       Dosage: Hypertens: Init.2,5 mg dly in pts.not on diuret. Incr.to 5 mg   Side effects: Angioed., bld.dyscras., orthostat. effs., tachycard., CNS   K salts/ K -cont. salt substit./Li/dantrolene infus., concom. aliskiren,
                                                                   +
                                                                       +
       and max.10 mg dly.at 2-4 wks. interv.depend.on respons.  effs., hyperkalaem., hyponatraem., GI-disturbs., ren.dysfunct., ac.ren.   diabet.mellit./ren.impairm., concom sacubitril/valsartan, extracorpor.
       Post MI: Init. 2,5 mg 2xdly x2 days 3-10 days aft.ac.MI if heart fail   fail., impot., hepatit., asthen., cough., bronchosp., rhinit.,  sinusit., skin   treatm. lead.to contact of bld.with neg.charg.surfac , pregn., lactat.,
       manifests & pt. haemodynamic stable. incr.to 5 mg 2xdly if well tol.   reacts.incl tox. epiderm. necrolys/ Stev.Johns.syndr. & erythema mul-  sev.hypotens., shock incl. cardiogen., left ventr.outflow-tract obstruct.,
       If init.dos.of 2,5 mg not tol.init.with 1,25 mg 2xdly incr.to 2,5 mg 2xdly.  tiforme., fev./vasculit./myalg./+ANA & elev.ESR.  unstab. HF aft.ac.MI, safety & effic.of amlodipine in hypertens.cris.
       Non-diabet.& diabet.nephropathy: Init.1,25 mg dly. Accord.  Special precautions: Cerebrovasc./ischaem. heart dis., vol.deplet.   not est., effic.& tol.not est.in childr.& adolesc.
       to respons.doubl.dos.at 2-3 wk.interv. Max. 10 mg dly. Consid.dis-  pts., sev.autoimmune dis., ac.MI with evid.of ren.dysfunct./at risk   Side effects: V.common: Oed. Common: Dysgeus., paraesthes.,
       cont.diuret.for 2-3 days bef. init.treatm.or at least reduc.diuret.dos.  of hypotens./at risk of furth.haemodynam.deteriorat. aft.vasodilat.  diplop., palpitats., flush., joint swell., musc.cramps, fatig., dizzin.,
       High risk. indiv: Discont.diuret.2-3 days bef.init therap. Where diu-  treatm., bone marrow.depress., diab. mellit., hyperkalaem., spec.su-  headache, vis. disturbs., tinnit., vertigo, hypotens., dyspn., cough,
       ret.cannot.be discont.init.with. reduc. diuret.dos. Subseq.dos.adjustm.  pervis.if admin.in sev.resist.hypertens.in renovasc.dis., imp.ren. funct.,   abdom.pain, N&V, dyspeps., alter.bowel habits, diarrh., constipat.,
       depend. therapeut. respon.    anaphylact.reacts.with desensitis. protocols/ high flux membr.dialys.,   prurit., rash, exanthema, asthen. Uncommon: Rhinit., eosinopil., hy-
       MI/stroke/CV death risk reduct.: Init: 2,5 mg once dly. Incr.grad.  incr.incid.of angioed.in black pts., cross.placenta, surg.& anaesth.  persens., allerg.reacts., hypoglycaem., hyperkalaem., hyponatraem.,
                                              +
       depend.on tol.in which case dos. should be doubl.aft.one wk & doubl.  Drug interactions: K -supplem./-spar.diuret. incr. hyperkalaem.risk,   insomn., mood changes, depress., sleep disturbs., somnol., trem., hy-
       again aft. 3 wks. to usual maint.dos.of 10 mg once dly.  diuret./alcoh.& antihypertens. potent. respons., antihypertens. eff.re-  poaesthes., syncope, tachycard., dysrhythm., vasculit., bronchosp., dry
       Contraindications: Angioed.hist.with prev.ACE/ ARB ther., heredit./  duc.by indomethac.& NSAIDs, Li-conc.incr.  mouth, angioed.of face/extremit./lips/mucous membr./ tong./glott.&/
       idiopathic angioed., aort. stenos., hypertrop.obstruct.cardiomyopathy,   RAN-PERINDOPRIL 4, Ranbaxy [P/S]  larynx, alopec., purpura, skin discolourat., hyperhidros., urticar., photo-
       sev imp. ren funct., ren.artery stenos.in pts.with sngl. kidn., concom.  Perindopril tert-butylamine  sens. reacts., pemphig., arthralg., myalg., back pain, micturit.disord.,
       K  spar.diuret.ther., porphyr., dialysis. pts., pregn.& lactat., safety &   Indications: Mild to mod.hypertens., CHF not adeq. control.by con-  noctur., incr.urin.freq., ren. impairm., erect.dysfunct., gynaecomast.,
        +
       effic in childr.not est.      vent.ther.with diuret.& digital. & where vasodilat.indicat, CV event   periph. oed., chest pain, pain, malaise, pyrex., weight incr./-decr.,
       Side effects: Angioed., bld.dyscras., orthostat. effs., tachycard.,   risk reduct.in stable coron.artery dis.without HF.  bld.urea & ser.creatin.incr., fall; Rare: Psorias.aggrav., confus.state,
       dizz., headache, fatig, mood.alt, sleep disturbs., hyperkalaem., hy-  (S3) TABS, 42/7.1.3/0107  ser. bilirubin & liv.enzym.elev. V rare: Hyperglycaem., hyperton.,
       ponatraem., GI-disturbs., ren.dysfunct., ac.ren.fail., hepatit., asthen.,   710611-001: 4 mg, 30, R52,40  periph.neuropathy, MI/ cerebrovasc. accid. poss.second.to excess.
       cough.,bronchosp.,skin reacts.incl tox.. epiderm. necrolysis/Stev.  Dosage: Mild to mod.hypertens:Init.4 mg dly. bef. breakf., may   hypotens.in high risk pts, ang.pector. gastrit., hepatit., jaund., hepat.
       Johns.syndr.& erythema multif., allerg.reacts.  be incr.to 8 mg as sngl.dos.aft.1 mnth. of treatm.accord.to respons.  enzymes incr., Quincke’s oed., erythema multif., exfoliat.dermatit.,
       Special precautions: Cerebrovasc./ischaem. heart dis., salt/vol.  CHF: Init. 2 mg as sngl.dos.in morn., may be incr.to 4 mg once   ac.ren.fail., haemoglob. & haematocrit decr., leucopen./neutropen.,
       deplet. pts., sev.autoimmune dis., ac.MI with evid.of ren.fail./at   BP accept.  agranulocytos./pancytopen., thrombocytopen., haemolyt.anaem.in
       risk of hypotens., bone marrow.depress., diab.mellit., hyperkalaem.,   CV event risk reduct: Init.4 mg once dly.x2wks. incr. to 8 mg once   congenit. G-6PDH defic., eosinophil., pneumon., gingiv.hyperplas.,
       imp. ren. funct., anaplylact.reacts. with desensitis.protocols/high flux   dly.depend.on ren.funct  pancreatit., Stev.-John.syndr., hepatit. Unknown: Extrapyramid.
       membr.dialys., incr. incid.of angioed.in black pts., surg.& anaesth.  Contraindications: Angioed.hist.relat.to prev. ACE-inhibit.ther./  disord., tox.epiderm. necrolys.
       Drug interactions: Diuret.& antihypertens. potent. respons., anti-  angiotens.recept.block., heredit./ idiopath.angioed., aortic stenos.,   Warnings and special precautions: No rechalleng. aft.angioed.
                         +
       hypertens.eff.decr.by NSAIDs, Li-conc.incr., K -supplem./-spar.diuret.   hypertroph. obstruct. cardiomyop., sev.ren.funct.impairm., ren. artery   react., pass.through placenta, discont.treatm.& switch.to diff. anti-
       incr. hyperkalaem.risk.       stenos.in sngl.kidn.pts., bilat.ren.artery stenos, concom.K-spar.diuret.  hypertens. class if a woman becom.pregn., discont. ther.if angioed.
       RAMIWIN, Zentiva [P/S]        ther., porphyr., concom. Li ther., pregn., lactat., concom. aliskiren cont.   assoc.with laryng. oed. occurs & init.appropr.monit./emerg.ther.,
       Ramipril                      prod., safety & effic.in childr.not est.  angioed. hist.unrelat.to ACE-inhib.ther., intest. angioed., no sacubi-
       Indications: Mild to mod.hypertens., card.fail. follow.MI., reduc.pro-  Side effects: Freq: Dizzin., headache, paraesthes., vertigo, vis.dis-  tril/valsartan within 36 hrs.of perindopril ther., benef.-risk.assessm.
       teinur.& glomerul.filtrat.rate decline in diabet.nephropathy & hyperten.  turbs., tinnit., hypotens., cough, dyspn., diarrh., abdom.pain, constip.,   bef.init. concom. NEP inhibits.as angioed.risk poss.incr., anaphylact.
       (S3) CAPS. W/7.1.3/233, 234   dysgeus., dyspeps., N&V, prurit., rash., musc.cramps., asthen. Less   reacts.dur.low-dens.lipoprot. aphores. with dextr.sulph./dur.hyme-
       704023-001: 2,5 mg, 30, R131,48  freq: Decr. haemoglob./ haematocr., thrombocytopen., leucopen., neu-  noptera desens. treatm., collag.vasc.dis./ immunosuppress. ther./
       704025-001: 5 mg, 30, R197,46  tropen., agranulocytos., pancytopen., eosinophil., haemolyt.anaem.,   concom. allopurinol/ procainamide esp.in case of pre-exist.imp.ren.
       Dosage: Hypertens: Init.2,5 mg dly in pts.not on diuret. Incr.to 5 mg   angioed. of face/extremit./lips/muc.membran./ tong./ glott./larynx.,   funct., white bld.cell monit.advis./pt.to report infect. signs, prim.hy-
       and max.10 mg dly at 1-2 wk. interv.depend.on respon.  hyperkalaem., hyponatraem., hypoglycaem., mood disturbs., sleep   peraldosteronism, CF, hepat. impairm., elderly, concom.NSAID/other
       Post MI: Init. 3-10 days aft.ac.MI if heart fail manifests &   disord., somnol., syncope, confus., palpitat., tachycard., ang.pect., dys-  meds.with antihypertens. eff., adeq.hydrat., concom. diurets., vol./salt
       pt.haemodynamic stable at 2,5 mg 2xdly x2 days incr.to 5 mg 2xdly   rhythm., MI, vasculit, stroke, bronchosp., rhinit., eosiniphil.pneumon.,   deplet., avoid in pts.suscept.to malign. hypertherm., concom.grape-
       if well tol. If init. dos.of 2,5 mg not tol.init.with 1,25 mg 2xdly incr.   dry mouth, pancreatit., hepatit., urticar., photosens., pemphig., hyper-  fruit juice not recomm., congen.G-6PDH defic., monit.ciclosporin lev.
       to 2,5 mg 2xdly.              hidros., erythema multifome, arthralg., myalg., ren,insuffic., ac.ren.fail.,   in ren. transpl.pts.on amlodipine, ren.funct./ BP/ ser. K  monit.in pts.at
                                                                                        +
       Non-diabet.& diabet.nephropathy: Init. 1,25 mg dly. Accord.  erect.dysfunct., chest pain, malaise, periph.oed., pyrex., sweat., incr.   high risk of sympt. hypotens., ischaem.heart/cerebrovasc.dis., mitral
       to respons.doubl.dos.at 2-3 wk.interv. Max.10 mg dly. Consid.dis-  bld.urea/bld.creatin./bld.bilirub./ hepat. enzym., fall.  valve stenos., discont.ther.in case of jaund.& mark. hepat. enzym.elev.,
       cont.diuret. for 2-3 days bef.init.treatm.or at least reduc. diuret. dos.  Warnings and special precautions: Do not re-challenge aft.an-  black pts., maj.surg./ dur. anaesthes., hyperkalaem.risk, diab.glycaem.
       Contraindications: Angioneurot.oed.hist., childr., pregn.& lactat.,   gioed.react., discont.if pregn. occurs/ contemplat., assess.benef./risk   contr. monit.esp.dur.1  mnth., concom.CYP3A4 induc./ inhibits., dual
                                                                           st
       imp.liv.funct., dialysis.pts.  if unstable ang. pect.occ.dur.1st mnth.of treatm.bef.contin. tream,   blockade of the RAAS, limit dos. of concom.simvastatin in pts.on
       Side effects: Naus., dizz., headache, cough, hypotens., hyperkalaem.,   symptomat.hypotens., disc.concom.diuret.2-3 days bef.init.ther. to   amlodipine to 20 mg/day, Lapp lact.defic./gluc.-galact. malabsorpt.
       angioneurot.oed., allerg. reacts., GI-disturbs., decr.Hb, bld.dyscras.  reduc.likelihood of sudd./ sev. hypotens., ren.impairm., discont.if   Interactions: Poss.incr.Li lev.& toxic., incr. adverse eff.risk with es-
       Special precautions: Teratogenic.in animals, if poss.discont.  incr.bld. urea & ser. creatin.occur with no appar.pre-exist. ren.dis.,   tramustine, NSAID’s & high dos. salicylate poss.reduc.antihypertens.
       diuret.2-3 days bef.commenc.ther. otherwise init.dos.should be   incr ren.fail.risk esp.in CHF pts., anaphylact. reacts.exp.in pts.on ACE   eff., hypoglycaem.eff.of insul.& hypoglycaem. agents incr., incr.angi-
       1,25 mg, salt & vol. deplet.pts., CHF, imp.ren.funct., renovasc.dis.,   inhib.being desensitis.with hymenoptera venom or in haemodialys.   oed.risk with concom.mTOR inhibits (eg.sirolimus, everolimus, tem-
       liv.impairm., surg.& anaesthes., monit.WBC & prot. urine lev.with   using cert. high-flux membr./low density lipoprot.apheres.with dextr.  sirolimus)/ gliptines (eg. linagliptin, saxagliptin, sitagliptin, vildaglip-
       collagen vasc.dis.where assoc. with imp.ren.funct.& concom.cor-  sulfate, no exper. in rec.ren.transpl., discont.ther.immed.& appropr.   tin)/ ACE-inhibits/racecadotril, poss. excess. BP reduct.with diurets.,
       ticoster.& antimetabol.       treatm.if angioed./ ser.hypersens.reacts. occur, incr.angioed.incid.in   poss.reduc. antihypertens. eff.with sympathomimets., nitritoid reacts.
       Drug interactions: K-spar.diuret.& meds to treat hypokalaem.incr.  black pts., sev.liv.funct. impairm., discont.ther.if jaund./mark.hepat.en-  with concom.inject.gold, grapefruit juice incr.bioavail., concom.tac-
       hyperkalaem.risk, diuret.& antihypertens. potent.respons., attenuate   zym. elev.devel., WBC monit.& pt.to report infect.signs esp. in collag.   rolimus bld. lev.incr., concom.simvastatin expos.incr., baclofen potent.
       K-loss from thiazides, Li-conc.incr., antihypertens.eff. decr. by NSAID’s  vasc. dis./concom.immunosuppress. ther./ allopurinol/ procainamide,   antihypertens.eff., incr.eff.with nitroglycer./ other nitrat./vasodilat./</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page141.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page137.html">137</a>&nbsp;&nbsp;&nbsp;<a href="page138.html">138</a>&nbsp;&nbsp;&nbsp;<a href="page139.html">139</a>&nbsp;&nbsp;&nbsp;<a href="page140.html">140</a>&nbsp;&nbsp;&nbsp;<a href="page141.html">141</a>&nbsp;&nbsp;&nbsp;<a href="page142.html">142</a>&nbsp;&nbsp;&nbsp;<a href="page143.html">143</a>&nbsp;&nbsp;&nbsp;<a href="page144.html">144</a>&nbsp;&nbsp;&nbsp;<a href="page145.html">145</a>&nbsp;&nbsp;&nbsp;<a href="page146.html">146</a>&nbsp;&nbsp;&nbsp;<a href="page147.html">147</a>
             </td>
             <td width="35%"><a href="page143.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page143.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
